Universal Cells
Mary Prieve is currently serving as the Executive Director and Head of R&D at Universal Cells. Prior to this, Mary held positions such as Senior Director of Discovery Research at Deverra Therapeutics and Nohla Therapeutics. With a strong background in biology, Mary has also worked at PhaseRx, Inc, Nastech Pharmaceutical, and various academic institutions such as University of Washington, Seattle University, and Smith College. Mary holds a Bachelor of Science in Chemistry from UC Santa Barbara and a Doctor of Philosophy in Biology from the University of California, Irvine - College of Medicine.
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.